Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical ...

Four biotech stocks in the IBD 50 are in bases as first-quarter earnings rolls in. Travere Therepeutics is below a buy point ...

Full FDA approval covers proteinuria reduction in FSGS without nephrotic syndrome, a defined clinical subset differentiated ...

Regeneron and Telix announced a strategic radiopharma collaboration worth up to $4.3 billion. Daiichi Sankyo entered a $1.55 ...

Travere Therapeutics just saw its modeled fair value per share move slightly, from US$42.36 to US$42.50, in the latest analyst update. That modest shift sits against a backdrop of Street research ...

The latest health news includes calls for transparency in FDA's accelerated drug approvals, expanded use of Travere's kidney drug, Roche's new study for gene therapy, and Hetero's global drug rollout ...

This week, the FDA flexed its regulatory authority to approve the first medicine to treat focal segmental glomerulosclerosis, ...

Recent advancements in health news highlight the FDA's approval of Travere's drug for a rare kidney disease, new AI tools for ...

Travere Therapeutics saw an improvement in its IBD SmartSelect Composite Rating Wednesday, from 94 to 97.

Filspari is now indicated for patients with focal segmental glomerulosclerosis without nephrotic syndrome to target significant proteinuria reduction.

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Travere Therapeutics’ sparsentan receives US FDA nod to treat focal segmental glomerulosclerosis; the first and only approved medicine for FSGS: San Diego Wednesday, April 15, 2 ...